Company overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing KPRX with another company.
| Daily close (USD) | $2.53 |
| Market capitalization (USD) | $11,193,699.11 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.66 |
No matching rows. Clear the filter to see all records.
Read KPRX's valuation metrics
Company size
Kiora Pharmaceuticals, Inc. Common Stock's recorded market capitalization is $11,193,699.11. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
KPRX's recorded price-to-book ratio is 0.66. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Kiora Pharmaceuticals, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about KPRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow KPRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.